Bengt Hallberg

This study identifies RUVBL1 and RUVBL2 as druggable regulators of MYCN in neuroblastoma, showing their inhibition reduces MYC signaling and induces cell cycle arrest and apoptosis.

This study shows that combining ATR and ALK inhibitors improves survival in MYCN-amplified neuroblastoma mouse models lacking ALK mutations.

This study identifies FGFR2 as a driver of resistance to lorlatinib in ALK-expressing neuroblastoma and shows that FGFR inhibition synergizes with lorlatinib to improve outcomes.

The paper introduces CLEAN, a web tool for exploring neuroblastoma data, focusing on DNA damage response to identify drug targets.

This study identifies ALK signaling's role in enhancing DNA damage response in neuroblastoma, showing that combined ATR/ALK inhibition leads to sustained tumor response and differentiation.